Lentiviral gene therapy delivering VIP complementary DNA to arthritic joints reduced inflammation and joint destruction in a mouse collagen-induced arthritis model — proof-of-concept for neuropeptide gene therapy in autoimmune disease.
Key findingLentiviral VIP gene delivery to arthritic joints reduced inflammation, cartilage destruction, and bone erosion in collagen-induced arthritis mice — de
What the researchers found
Lentiviral VIP gene delivery to arthritic joints reduced inflammation, cartilage destruction, and bone erosion in collagen-induced arthritis mice — demonstrating neuropeptide gene therapy as a viable approach for local treatment of autoimmune joint disease.
Why it matters
Relevant for neuropeptides, inflammation, immune-function.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.
Arthritis and rheumatism, 58(4), 1026-37
Citation
Delgado, Mario; Toscano, Miguel G; Benabdellah, Karim; Cobo, Marien; O'Valle, Francisco; Gonzalez-Rey, Elena; Martín, Francisco. (2008). In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.. Arthritis and rheumatism, 58(4), 1026-37. https://doi.org/10.1002/art.23283